Alzheimer’s disease is the most common age-related neurodegenerative disorder, characterized by the progressive degeneration of neuronal populations and the simultaneous loss of memory and cognitive functions.
Methyllycaconitine is an alpha-7 nicotinic acetylcholine receptor specific antagonist with brain penetrance. NEUROFIT has developed this model because these receptors play a central role in Alzheimer’s disease.
Alpha-7 nicotinic acetylcholine receptor agonists or PAM alpha-7 are usually tested in this model but other treatments could also be considered. Please feel free to contact us to discuss the feasibility of your study.
☐ Percentage of alternation in the T-Maze (memory performance)
T-MAZE Continuous Alternation Task (T-CAT) in mice
Donepezil : Reversion of Methyllycaconitine-induced cognitive deficit in the T-Maze alternation task in the mouse
Memantine : Reversion of Methyllycaconitine-induced cognitive deficit in the T-Maze alternation task in the mouse
You could also be interested in
Scopolamine, a muscarinic receptor antagonist is widely used to induce cognitive / memory impairment in clinical research.
This model is probably the most representative of the human Alzheimer's disease.
Amyloid β : animal model
Amyloid-β i.c.v injection induces learning deficits and a dysfunction of the cholinergic system.
Amyloid β : cellular model
Intoxication of neuronal cultures with Aβ has been widely used to understand some of the mechanisms of cell death in AD and thus represents an instrumental in-vitro system to evaluate the efficiency of new drug candidate.